CG Oncology: Bladder Cancer Specialist Sets Course for First Approval
Reading Time: 3 minutes
CG Oncology is nearing the commercialization of Cretostimogene as a new oncolytic immunotherapy for the treatment of bladder cancer. Phase 3 study data demonstrate a response rate of 75.5% in HR-NMIBC. The FDA submission is planned for Q4. No significant product revenues expected before 2027 is a risk factor. With liquid assets of around 1 billion USD, financing is secured until 2029. CG Oncology (CGON) is a biopharmaceutical company in late clinical development primarily focused on the research and commercialization of oncolytic...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
